Lippis Daniel J. 4
4 · Edwards Lifesciences Corp · Filed Dec 12, 2025
Insider Transaction Report
Form 4
Lippis Daniel J.
CVP, TAVR
Transactions
- Exercise/Conversion
Common Stock
2025-12-12$59.26/sh+1,019$60,383→ 23,020.91 total - Sale
Common Stock
2025-12-12$84.03/sh−1,019$85,625→ 22,001.91 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2025-12-12−1,019→ 5,095 totalExercise: $59.26From: 2020-05-08Exp: 2026-05-07→ Common Stock (1,019 underlying)
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $83.58 to $84.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.